InvivoSciences, Inc. (IVS) articles

Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardio­vascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and phenotype by adopting a personalized treatment methodology for cardiovas­cular diseases. Established in 2001 in St  Louis, Missouri,lnvi

InvivoSciences, Inc. is collaborating with Drs. Elson and Qian to establish a novel mathematical model to understand the development of cardiac fibrosis during heart failure. The model will be used to identify and validate new therapeutic targets to prevent, slow, or reverse cardiac fibrosis.